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Abstract
Background: Available bacterial genomes provide opportunities for screening vaccines by reverse vaccinology. Efficient
identification of surface antigens is required to reduce time and animal cost in this technology. We developed an approach
to identify surface antigens rapidly in Streptococcus sanguinis, a common infective endocarditis causative species.
Methods and Findings: We applied bioinformatics for antigen prediction and pooled antigens for immunization. Forty-
seven surface-exposed proteins including 28 lipoproteins and 19 cell wall-anchored proteins were chosen based on
computer algorithms and comparative genomic analyses. Eight proteins among these candidates and 2 other proteins were
pooled together to immunize rabbits. The antiserum reacted strongly with each protein and with S. sanguinis whole cells.
Affinity chromatography was used to purify the antibodies to 9 of the antigen pool components. Competitive ELISA and
FACS results indicated that these 9 proteins were exposed on S. sanguinis cell surfaces. The purified antibodies had
demonstrable opsonic activity.
Conclusions: The results indicate that immunization with pooled proteins, in combination with affinity purification, and
comprehensive immunological assays may facilitate cell surface antigen identification to combat infectious diseases.
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Introduction
With antibiotic resistance increasing rapidly among bacterial
pathogens because of antibiotic overuse, more attention has been
paid to vaccine identification against bacterial diseases. Most
successful vaccines against bacterial pathogens are those in which
an immune response against a toxin (e.g. tetanus) is elicited. While
pathogen attenuation has had much success with viruses, it is rare
to see an attenuated version of a bacterial or parasitic pathogen
used as a vaccinogen. Thus, the choice is generally limited to
immunization with killed pathogens, where success rates have
been quite variable [1] and side effects may be a concern. As the
genomes of many pathogenic bacteria have become available, a
new systematic approach for identification of vaccine candidates,
termed reverse vaccinology [2,3] has been developed. This
approach brings conventional subunit vaccines into the modern
era based on genome sequences. The process begins with the
identification of all putative surface proteins, which are a logical
choice for vaccine candidates. The surface proteins can be
predicted from genomic sequences using computer programs
based on signal peptides, LPXTG motifs, transmembrane helices
and other surface protein prediction algorithms. The candidate
genes are then cloned and the proteins expressed in E. coli. The
immune responses of animals to the proteins are determined after
injection of the purified proteins. This approach was first
successfully applied to identify vaccine candidates in Neisseria
meningitidis [2] and has since been applied to identify vaccine
candidates for other bacterial pathogens including Streptococcus
pneumoniae [4], Streptococcus agalactiae [5], Staphylococcus aureus [6],
Porphyromonas gingivalis [7], Chlamydia pneumoniae [8], Bacillus anthracis
[9], Streptococcus suis [10] and Echinococcus granulosus [11].
Although several vaccines have been identified by reverse
vaccinology, there are two bottlenecks in this approach: (1) the
expression of a large number of proteins is technically difficult and
time-consuming; and (2) the examination of each protein in animal
models is expensive and laborious. To overcome these problems,
we developed an approach to identify candidate proteins by
comparative genomics, to use an antigen pooling approach for the
immunization regimen and to examine antigenicities of specific
candidates in Streptococcus sanguinis. S. sanguinis is an indigenous and
important opportunistic gram-positive human oral bacterium that
has long been recognized as one of the principal causative agents
of infective endocarditis (IE) - a serious heart disease [12]. We
focused our search on both lipoproteins (Lpp) and cell wall-
anchored (CWA) proteins that we believed were most likely to be
effective vaccines via comparative genomics [13].This both
decreases the amount of effort required with respect to PCR
amplification, gene cloning and protein expression and gives a
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greater chance of success. By combination of the comparative
genomics analysis and pooled antigen approach described, several
surface-exposed proteins with strong antigenicity were identified in
S. sanguinis. It should be noted that there are many bacterial and
parasitic pathogens in which no successful vaccine strategy is
available. Thus, this approach may be applied for evaluating
antigens in the identification of subunit vaccines for other
important clinical pathogens.
Results
Criteria for selection of vaccine candidates
To identify potential vaccine candidates, we compared surface-
exposed proteins with literature-reported vaccines. We first used
the S. sanguinis genome sequence to predict all putative proteins
containing signal peptide sequences by SignalP [14]. Over 360
ORFs with signal peptides were identified. We also predicted
transmembrane proteins by TMHMM [15]. There were over 600
ORFs predicted by TMHMM to possess transmembrane
domains. The surface proteins were then compared with reported
vaccines in streptococci. We found that two classes of proteins,
Lpp and CWA, were frequently found in successful vaccines. For
example, Wizeman et al [4] examined 108 putative surface
proteins in S. pneumoniae, and six were protective in mice. Two of
these proteins were CWA proteins and two were Lpp. To study
Lpp vaccinogens, Lei et al [16] immunized mice with 16 S. pyogenes
Lpp, and five produced antisera with growth-inhibitory activity
against S. pyogenes. Numerous studies examining individual Lpp
proteins have also identified these proteins as effective vaccinogens
[17–27]. The hypothesis that Lpp and CWA proteins are useful as
vaccine candidates is further supported by Maione et al [5] who
examined 312 putative surface proteins of S. agalactiae for vaccine
efficacy in mice. Three of four final protective proteins in this
study were CWA proteins.
We therefore performed further bioinformatic analyses to
identify all putative S. sanguinis ORFs belonging to both classes
(see Materials and Methods, and [28,29]). We identified 60 Lpp
and 38 CWA in the S. sanguinis genome. Additionally, all putative
Lpp and CWA proteins were examined for the number of
transmembrane domains using the TMHMM program [15].
Proteins with more than two transmembrane domains were
removed from the list. Not only are proteins with a high number of
hydrophobic transmembrane domains very difficult to express in
E. coli [30], they are also more likely to be misclassified membrane
proteins buried beneath the gram-positive cell wall. We next
eliminated from this list those proteins that were not conserved
among streptococcal genomes. The rationale for this decision is
that conserved proteins are more likely to possess important
biological functions that prevent their antigenic variation. In
addition, several streptococcal species are known to cause IE [31].
We would want a polyvalent vaccine to have broad protection
against different streptococcal species [32]; thus, such conservation
is desirable. We identified conserved proteins by comparative
genomic analyses. Forty-seven conserved proteins including 28
Lpp and 19 CWA were identified based on the presence of
orthologs in at least two other streptococcal species (Table 1). We
found that about half of the listed proteins were homologs of
leading vaccine candidates in other streptococci (Table 1)
including 8 of the 19 CWA candidates and 16 of 28 Lpp
candidates.
Immunization with pooled proteins
The two most common animal models of endocarditis are
rabbit [33] and rat [34], both of which have been employed by our
group [35]. Both models require a relatively complicated
procedure to establish IE, including insertion of a catheter through
the carotid artery to the aortic valve, intravenous inoculation, and
recovery of bacteria from vegetations on the aortic valve [35]. The
complexity of the model precludes the individual screening of a
large number of candidates. To reduce the number of animals
required, we pooled candidate proteins together for immunization.
To examine whether this strategy worked, we randomly picked
eight protein candidates from Lpp and CWA to pool together. To
compare the immunogenicity of other surface proteins, one
putative secreted protein 61 and one putative surface-associated
protein 62 based on signal peptide sequences predicted by SignalP
3.0 and TMHMM were put into the pool. The 10 proteins were
used to immunize rabbits. Ten proteins were expressed in E. coli as
described in Materials and Methods. To facilitate solubility and
purification of the protein in E. coli, the region encoding
hydrophobic transmembrane domains predicted by TMHMM
in each ORF were excluded. After purification (Fig. 1A),
equimolar amounts of each protein (total 1mg) were pooled to
immunize and boost rabbits (see Materials and Methods). An
equal amount (1 mg) of recombinant His-tagged P. gingivalis Kgp
protein [25] was used for sham immunization.
To examine the reactivity of each component of the pool in
immunization, a Western blot of antiserum against each protein
was performed. The result showed that all ten proteins in the pool
were immunogenic in rabbits (Fig. 1B). There was no reactivity of
the immune serum to the recombinant sham antigen nor was there
any reactivity of any of the proteins to the pre-immune serum
(data not shown).
We used indirect enzyme-linked immunosorbent assay (ELISA)
to detect the titer of the antiserum against specific antigens. The
optimal concentrations of the reagents for ELISA were first
examined by a criss-cross serial dilution with two-fold dilutions of
antigen and anti-sera. The results indicated that the optimal
concentration of the antigens on ELISA plates was 1–2 mg/ml.
Therefore, 2 mg/ml of each antigen was used to coat plate wells in
ELISA examination of the titer of immune sera. The pre-immune
serum was used as the negative control. The results showed the
antisera produced by pool immunization had greater reactivity
against each purified antigen than the sham in the ELISA (Fig. 1C).
Proteins 1, 8, 20, 21, and 44 elicited the highest immune responses
in rabbits. Proteins 61 and 62 elicited lower reactivity.
We also examined surface reactivity of the antiserum using
whole S. sanguinis-cell ELISA as described [36]. The whole-cell
ELISA titers of pre-immune serum, 21-d antiserum and 42-d
antiserum were 0, 128 and 32768, respectively. Thus, strong
reactivity was observed at 42 days post-immunization (i.e., 21 days
after boost immunization). However, there was no appreciable
reactivity to surface proteins in the pool-immunized rabbits prior
to vaccination and only slight reactivity at the time of the boost.
These data strongly implied surface expression of at least some of
the pooled proteins.
Isolation of antigen-specific antibody by affinity
purification
The eventual goal of reverse vaccinology is to identify individual
vaccine candidates. The pool approach above significantly
increased the efficiency of vaccine screening. However, it
produced an antiserum with activities against all component
proteins. In order to determine the relative importance of
individual pool components, we established an affinity chromato-
graphic method to purify antibodies from the antiserum (see
Materials and Methods). Each antibody was affinity purified by a
specific column covalently linked with a purified protein. The
S. sanguinis Surface Antigens
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Table 1. Conserved Lpp and CWA proteins in S. sanguinis SK36.
IDa SSA# Lpp CWA VHb Description
1 SSA_0138 + + Metal-binding (Zn)
2 SSA_0588 + + L-cystine ABC transporter, substrate-binding component
3 SSA_0260 + + Manganese/Zinc ABC transporter substrate-binding protein
4 SSA_1340 + + Zn/Mn ABC-type porter lipoprotein
5 SSA_0941 + + ABC-type phosphate transport system
6 SSA_1742 + + Ferrichrome-binding protein
7 SSA_1990 + + Zn-porter lipoprotein
8 SSA_1038 + Lipoprotein
9 SSA_0375 + D-methionine-binding lipoprotein (ABC-type transporter)
10 SSA_1298 + Maltose/maltodextrin ABC transporter, sugar-binding protein
11 SSA_2165 + + ABC-type oligopeptide transporter, periplasmic component
12 SSA_1066 + + ABC-type oligopeptide transport system
13 SSA_1948 + + Oligopeptide-binding lipoprotein precursor
14 SSA_1949 + + AliA protein
15 SSA_1950 + + ABC-type oligopeptide transport system, periplasmic component
16 SSA_1729 + ABC transporter substrate-binding protein-branched chain amino acid transport
17 SSA_1277 + D-alanyl-D-alanine carboxypeptidase
18 SSA_2139 + Membrane protein (preprotein translocase) oxaA 1 precursor
19 SSA_1629 + Peptidyl-prolyl cis-trans isomerase, cyclophilin-type
20 SSA_0893 + ATP-binding cassette transporter-like protein
21 SSA_0753 + + Foldase protein prsA precursor
22 SSA_2196 + Hypothetical protein
23 SSA_0074 + ABC transporter substrate-binding protein-sugar transport
24 SSA_1122 + + Thioredoxin family protein
25 SSA_1117 + + Hypothetical protein
26 SSA_1581 + + Metal-binding ABC transporter
27 SSA_1003 + ABC transporter substrate-binding protein-multiple sugars
28 SSA_2352 + ABC-type nitrate/sulfonate/bicarbonate transporter
29 SSA_0956 + + Surface protein D
30 SSA_0904 + CshA-like fibrillar surface protein A
31 SSA_1663 + + Collagen-binding protein A
32 SSA_0565 + Hypothetical protein
33 SSA_1112 + Cell wall surface anchor family protein
34 SSA_1633 + + FimA fimbrial subunit-like protein
35 SSA_1632 + + Surface protein
36 SSA_0905 + + CshA-like fibrillar surface protein B
37 SSA_1634 + + Heme utilization/adhesion exoprotein
38 SSA_0303 + Surface protein C
39 SSA_2023 + Fructan beta-fructosidase precursor
40 SSA_0453 + Type II secretory pathway, pullulanase PulA glycosidase
41 SSA_1234 + 59-nucleotidase
42 SSA_0243 + 29,39-cyclic nucleotide 29-phosphodiesterase/39-nucleotidase bifunctional periplasmic precursor protein
43 SSA_1591 + Dipeptidase
44 SSA_0146 + + DNA repair ATPase
45 SSA_1666 + + Collagen-binding surface protein
46 SSA_1019 + Collagen-binding surface protein
47 SSA_0805 + Collagen-binding surface protein
aID, identifying number (numbers in bold indicate pool proteins).
bstreptococcal vaccine homolog.
doi:10.1371/journal.pone.0011666.t001
S. sanguinis Surface Antigens
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concentration of each purified antibody was determined by
OD280. The antibodies were adjusted to equal values and the
specific titer, specificity, and purity of each purified antibody was
determined using ELISA (Fig. 2). The results suggested that the
affinity-purified antibodies were successfully separated using our
method. Except for Ab 62, each of the affinity-purified antibodies
showed high titers against their specific antigens and very low titers
against other proteins.
Cell surface exposure of candidate proteins
To determine exposure of the pooled proteins on the S. sanguinis
cell surface, competitive ELISA and Fluorescence-Activated Cell
Sorting (FACS) analyses were carried out using affinity-purified
antibodies, antigens and bacterial whole cells. For competitive
ELISA analysis, each affinity-purified antibody was incubated in
the presence or absence of its cognate purified antigen, followed by
addition to microtiter wells coated with whole S. sanguinis cells
(Table 2). The results indicated that all 10 affinity-purified
antibodies had reactivity to S. sanguinis SK36 whole cells, but, as
expected, had less reactivity than whole antiserum. Whole-cell
ELISA titers of 9 purified antibodies pretreated with their antigen
proteins exhibited significantly reduced activity when compared to
untreated purified antibody, especially antibodies against proteins
1, 8 21 and 31 (Table 2). FACS analysis of S. sanguinis SK36 whole
cells was also performed with affinity-purified antibodies, in the
presence and absence of cognate antigens (See Materials and
Methods). All 10 purified antibodies produced greater signal
intensities than pre-immune serum; FACS values of all purified
antibodies except for 62 markedly decreased after pretreatment
with specific antigens, especially those of Ab1, Ab8, Ab21 and
Ab31 (Fig. 3). This result was consistent with the competitive
ELISA (Fig. 2). Thus, both competitive ELISA and FACS
suggested that at least 9 of 10 selected proteins were exposed on
the S. sanguinis SK36 cell surface.
Opsonization activities of affinity-purified antibodies
The specific phagocytic activity in the presence of each affinity
purified antibody was analyzed in vitro as described [37]. Human
polymorphonuclear leukocytes (PMNs) was purified from buffy
coat blood and mixed with a fresh culture of S. sanguinis SK36. The
same amount of each purified antibody based on protein
concentrations was used in the assay. The original pre-immune
serum and antiserum were used as negative and positive controls,
respectively. Reactions without PMNs, without rabbit complement
or without antisera were also examined for background. After
incubation for 0 or 1 hr, bacterial cells were plated on BHI plates
to determine bacterial killing. The bacteria were efficiently
phagocytized in the presence of the purified antibodies. Nine of
ten purified antibodies exhibited significant enhancement of S.
sanguinis SK36 phagocytosis by PMNs compared to pre-immune
serum or bacteria alone (Fig. 4). In addition, the phagocytic
activity in pool-immunized serum was higher than those of
individual purified antibodies at the same protein concentrations.
The result indicated the possibility of synergistic activity of the
antibodies.
Discussion
Since reverse vaccinology was first developed, there have been
several successful applications of this technology to identify vaccine
candidates against bacterial pathogens [2,4–11]. In these cases,
however, vaccine candidates were eventually obtained through
screening individually selected proteins in animal immunization
and protection tests. When an infection animal model is not
available (such as for emerging pathogens or for dangerous
pathogens with high virulence) or the infection animal model is too
complicated to screen a large number of candidates, vaccine
candidate discovery may be delayed. It also should be noted that a
genome-wide screen for vaccine candidates requires a large
number of animals and significant time and expense. To solve
the problem, we sought to improve this technique by using a
pooling strategy in which candidate antigens were combined for
immunization and applied comprehensive immunological assays
to testing the possible correlates of protection without an infection
animal model. This approach will not only decrease the
experimental animal usage and reduce time cost for vaccine
candidate identification, but also provide a potential assay for
synergistic activity between antigens.
We pooled 10 selected proteins from S. sanguinis SK36 to
immunize rabbits. After pooled immunization, all antigens in the
pool elicited immune responses, most of which were high-titer,
suggesting that the pool size did not limit immunogenicity (Fig. 1).
The antigen-specific fractions of the antiserum were successfully
purified by affinity chromatography (Fig. 2). Our result indicated
that 9 of 10 affinity-purified antibodies had reactivity to their
Figure 1. Characterization of the antibody response to pooled
antigens. A. Examination of the purified, His-tagged recombinant
proteins indicated above each lane by SDS-PAGE. B. Western blot of the
antigens shown in A reacted with anti-pool antiserum. C. ELISA of the
antigens shown in A reacted with anti-pool antiserum. The ELISA was
performed in triplicate, and the mean values and standard deviations
are shown.
doi:10.1371/journal.pone.0011666.g001
S. sanguinis Surface Antigens
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specific antigens on the S. sanguinis SK36 cell surface either by
competitive whole-cell ELISA assay or by FACS (Table 2 and
Fig. 3). These antibodies also promoted opsonophagocytosis of S.
sanguinis by human PMNs. Opsonophagocytosis is one of the
mechanisms of host defense against pathogen attack. This result
suggested the protective potential of each candidate could be
assessed via the opsonophagocytosis analysis. Therefore, our
approach will rapidly evaluate the immunogenicity and feasibility
of vaccine candidates prior to using an infection animal model.
Our results showed the reactivity to S. sanguinis whole cells of
unfractionated antiserum from pooled-protein immunization was
higher than that of individual antibodies purified from the same
antiserum (Figs. 3–4 and Table 2). Increased protection has been
also reported using mixed proteins as compared to any single
Figure 2. ELISA of affinity-purified antibodies against component pool antigens. Two-fold serial dilutions of affinity-purified antibodies
were added to microtiter plate wells coated with individual proteins. Assays were performed in triplicate, and the mean values and standard
deviations are shown. Values for cognate antigens were significantly greater than the values for all non-cognate antigens (P,0.05) except Ab62.
doi:10.1371/journal.pone.0011666.g002
S. sanguinis Surface Antigens
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protein in Leptospira kirschneri [38,39] and S. agalactiae [5]. In this
pooled-protein immunization approach, we not only evaluated the
potential protection of each antigen, but also obtained information
on synergistic activity of the antibodies that will be useful for more
powerful vaccine development from multiple antigens. Further-
more, due to the antigenic variability of the different strains within
a pathogen, multivalent vaccine approach may be the choice to
overcome the antigenic diversity [40]. It is possible to apply our
antigen-pooled immunization approach with multiple conserved
proteins to examine different strains of a pathogen to find the best
combination of multivalent vaccine candidates.
It should be noted that His tag may generate cross-reactive
antibodies and then affect the evaluation of pooled proteins
because each protein contains the His tag. This interference can
be reduced by prior incubation the antisera with the His tag
although our result showed the reactivity of the antisera to the His
tag was significantly lower than to each protein antigen (Fig. 1C).
There seems some cross-reactivity in the affinity purified
antibodies (Fig. 2), but the results from the competitive whole-
cell ELISA and FACS (Table 2 and Fig. 3) showed this cross-
reactivity did not influence the identification of antigenicity and
cell surface exposure of the candidates. This cross-reactivity may
be caused by the His tag, the limits of affinity purification, or
similar protein epitopes [41].
Surface-exposed proteins are regarded as pivotal players in the
infectious process of bacterial pathogens [42]. Two classes of
surface-exposed proteins, Lpp and CWA proteins, are quite
frequently found in reported vaccine candidates in streptococci,
including S. pneumoniae, S. agalactiae, S. pyogenes and S. parasanguinis
Figure 3. Flow cytometry of affinity-purified antibodies against S. sanguinis SK36 whole cells. Affinity-purified antibodies were incubated
with (gray line) or without (black line) the protein used for affinity purification, followed by incubation with S. sanguinis whole cells. Negative control,
pre-immune serum; positive control, anti-pool antiserum used for individual antibody purification. Values are representative of two independent
experiments. Values for protein treatments are significantly different from those of protein un-treatments (P,0.05) except for Ab62.
doi:10.1371/journal.pone.0011666.g003
Table 2. ELISA titers of affinity-purified antibodies against S.
sanguinis SK36 whole cells with and without pretreatment
with specific antigens.a
Serum or antibody Untreated (titer) Plus protein (titer) Inhibition (%)
Preserum 27 - -
Anti-sham 53 - -
Antiserum 54613 - -
Ab28 1024 512* 50
Ab23 512 256* 50
Ab61 512 256* 50
Ab31 3413 427* 88
Ab62 682 512 25
Ab20 512 213* 58
Ab8 32768 512* 98
Ab44 1024 427* 58
Ab21 6827 512* 93
Ab1 13653 512* 96
aTwo-fold serial dilutions of affinity-purified antibody was incubated with or
without 2 mg specific antigen for 1h and the ELISA titer against S. sanguinis
whole cells coated in microtiter plate wells were determined. Assays were
performed in triplicate and statistically significant differences between protein-
treated and -untreated were indicated (*, P,0.05). -, not determined.
doi:10.1371/journal.pone.0011666.t002
S. sanguinis Surface Antigens
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[4,5,16–27]. There may be two reasons for these findings. First,
Lpp and CWA proteins are common virulence factors [43]. The
functions performed by these proteins may be susceptible to
neutralization [44]. Second, Lpp and CWA proteins may be
surface-exposed naturally or due to their association with surface
structures [45] whereas most membrane proteins would be
predicted to be buried within the cell wall in streptococci. Here,
we identified 60 Lpp and 38 CWA proteins in the S. sanguinis SK36
genome by bioinformatics based on signal peptides, LPXTG
motif, and transmembrane helices. Many of them were homologs
of vaccines (Table 1). Interestingly, the eight tested Lpp and CWA
induced greater reactivity than the two other proteins (numbers 61
and 62) without the structure of Lpp and CWA, implying. that
Lpp and CWA proteins are more immunogenic. The high
percentage of confirmed surface proteins suggests the feasibility
of predicting vaccinogens by bioinformatics, which may also apply
to other emerging pathogens.
Five of the 10 candidates (1, 8, 20, 23 and 28) apparently belong
to ABC transport systems [28]. ABC transporters are involved in
uptake for metal ions, heme, amino acids, peptides, sugars,
phosphate, and other nutrients in bacteria. In S. pyogenes, five ABC
transporters of 16 Lpp have been shown to elicit protection in
mice blood against bacterial growth [16]. In S. pneumoniae, four
ABC transporters (PiuA, PiaA, PsaA and PotD) have been shown
to elicit protection in mice against S. pneumoniae disease [46–48].
FimA, which has been shown in our previous work to protect
vaccinated rats from endocarditis caused by different viridans
streptococci, is also an ABC transporter [25]. PiuA, PiaA, PsaA
and FimA are associated with not only iron, manganese, or zinc
ions uptake, but also virulence [46–49]. Protein 1 (AdcA), a Zn
ABC transporter, was demonstrated to be involved in endocarditis
virulence and biofilm formation in one previous study [50],
although an independently isolated mutant lacking the same
protein retained virulence [28]. We recently found S. sanguinis
SK36 SsaB, a homolog of FimA in S. parasanguinis, is a virulence
determinant in the rabbit endocarditis model [28]. Our results and
previous findings by others suggest that ABC transporters,
particularly those involved in metal ion uptake, are likely
candidates for vaccines against diseases caused by streptococci.
Protein 8 is a homolog of the PmpA protein of Borrelia burgdorferi
which was shown to be highly antigenic and contribute to the
genesis of Lyme arthritis [51,52]. Protein 21, PrsA, is an ortholog
of a peptidyl-prolyl isomerase. PpmA (i.e. PrsA) of S. pneumoniae
that has been associated with pneumococcal virulence [53].
Mutation of prtM (prsA-like) attenuated the virulence of Streptococcus
equi in a mouse model [54]. CWA protein 31 (CbpA) is a collagen-
binding protein suggested to be involved in platelet aggregation
[55]. Platelet aggregation is thought to play an important role in
causing bacterial endocarditis [55–58]. The mutation of CbpA in
S. sanguinis substantially inhibits its platelet aggregation compared
with the wild-type [59]. The data on homologs of proteins 1, 8, 21
and 31 in previous studies suggest these proteins may be involved
in virulence and have the potential to become vaccine candidates.
Interestingly, the antibodies affinity-purified by these four proteins
demonstrated stronger reactivity to the cell surface of S. sanguinis
than other tested Lpp and CWA proteins based on the consis-
tent results from both whole-cell ELISA and FACS ( Table 2
and Fig. 3). Among the 8 tested Lpp and CWA proteins,
nevertheless, there was no significant difference in the opsono-
phagocytic activities of their affinity-purified antibodies at equal
concentrations.
The two non-Lpp and CWA proteins examined in the pool had
different performances on the immunogenicity and opsonopha-
gocytic activity. With a signal peptide and no transmembrane
domain, protein 61 is probably a secreted protein. It is predicted as
a carbamate kinase. Carbamate kinase has been shown to be a
secreted or cell wall-associated protein in S. pyogenes [60], Salmonella
enterica [61] and Trichomonas vaginalis [62]. Carbamate kinase is one
of the three components of arginine-deiminase pathway identified
as a cell wall associated enzyme system in S. pyogenes [60]. This
pathway is absent in the majority eukaryotes including humans
and has been suggested as a vaccine candidate or novel drug
target. Here, protein 61 elicited an immune response in rabbits
(Fig.1C) that was reactive with whole cells (Table 2 and Fig. 3) and
which enhanced opsonophagocytic activity (Fig. 4). Protein 62, a
putative sugar-binding protein, is a surface–associated protein but
not Lpp and CWA protein based on its signal peptide and a
transmembrane domain. It possesses orthologs in S. gordonii and S.
mutans but not in S. pyogenens, S. pneumoniae, S. agalactiae or S.
thermophilus. To date, there is no report on the potential of this
protein to be a vaccine candidate in bacteria. Our results showed
protein 62 elicited immune responses but lower than those of Lpp
and CWA proteins in pool immunization (Fig. 1C). Its antibody
failed to be purified from pool-immunization antisera (Fig. 2)
because of low titer or an unknown reason, which prevented us
from determining its cell-surface exposure or opsonophagocytic
activity.
Taken together, most of 10 proteins we selected here were
shown to elicit strong immune response and the potential to
become vaccine candidates. The results also suggested that our
approach to predict vaccine candidates using bioinformatics and
examine the immune responses using pooled proteins will facilitate
vaccine development against emerging pathogens.
Materials and Methods
Animal ethics
Animals were treated humanely and in compliance with all
applicable federal guidelines and institutional policies. All of the
Figure 4. Opsonophagocytic activity of affinity-purified anti-
bodies. S. sanguinis cells were incubated with human PMNs, rabbit
complement and purified antibody for 1 hr (see Materials and
Methods). Log10 of bacterial CFU reduction between time 0 and time
1 hr are shown. Controls include pre-immune serum, without
complement, without PMNs, or bacteria only. Mean values and standard
deviations of at least triplicate assays are shown. Values for purified
antibodies are significantly different from the controls (P,0.05) except
Ab62.
doi:10.1371/journal.pone.0011666.g004
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procedures were approved by Virginia Commonwealth University
Institutional Animal Care and Use Committee.
Bacterial strains, plasmids and primers
S. sanguinis strain SK36, whose genome has been sequenced
[63], was grown at 37uC in brain heart infusion broth (BHI; Difco
Inc., Detroit, MI) supplemented with 1.5% agar as described
previously [50]. The strain was cultured under anaerobic
conditions. E. coli strains NovaBlue and BL21 (DE3) pLysS
(Novagen, Gibbstown, NJ) were used as hosts for plasmid
production and protein expression, respectively. Vector pET-46
Ek/LIC (Novagen) containing an N-terminal cleavable HisNTag
sequence was used in gene cloning and expression. Primers for
PCR amplification of selected genes are listed in Table 3. To
directly clone PCR fragments into pET-46 Ek/LIC vector without
ligation, each forward primer and reverse primer contained 59-end
sequence tails as described by the manufacturer.
Genomic analysis and surface protein prediction
To predict surface-exposed proteins, all ORFs in our annotation
of S. sanguinis genome were analyzed. The SignalP 3.0 program
[14] was used with the gram-positive setting to predict signal
peptides within 70 residues of the N-terminus of each ORF. The
TMHMM program [15] was used to identify transmembrane
proteins and locate hydrophobic domains. To identify lipopro-
teins, LipoP 1.0 [64] was used [28,64]. To recognize cell-wall
anchored proteins, the fuzzpro program in the EMBOSS package
[65] was used to identify the C-terminal signal containing the
LPXTG pattern [29].
Comparative genomic analyses were carried out to identify
conserved proteins in S. sanguinis using BLASTP as previously
described [13]. S. sanguinis proteins were compared to completed
streptococcal genomes downloaded from the NCBI protein
database. Significant matches (E,1e25) were analyzed to find
putative proteins with homologs in at least two other streptococcal
species. To evaluate the accuracy of computational prediction, we
collected all literature-reported leading vaccine candidates in
streptococci and downloaded their protein sequences from NCBI
databases. The sequences were compared with S. sanguinis proteins
to identify vaccine homologs.
Gene cloning and Protein purification
Predicted Lpp and CWA ORFs were selected for PCR
amplification. Because proteins with a high number of transmem-
brane domains are difficult to express, the regions encoding the
transmembrane domains predicted by TMHMM program in
ORFs were excluded. To directly clone the candidate genes, PCR
was performed using the specific pET Ek/LIC primers, S. sanguinis
SK36 genomic DNA template, and Platinum Taq DNA
Polymerase High Fidelity (Invitrogen, Carlsbad, CA). PCR
amplification was conducted as follows: 94uC for 1 min to
denature template; 30 cycles of 94uC for 30 s, 60uC for 30 s and
68uC for 1 min per kb of amplicon. The amplicons were purified
with a PCR purification kit (Qiagen, Valencia, CA), and mixed
Table 3. Properties and primer sequences for S. sanguinis pool-protein genes.
IDa SSA# Putative function Primers Sequences (59R39) Positionb MWc
28 SSA_2352 ABC-type nitrate/sulfonate/
bicarbonate transporter
28F GACGACGACAAGATCAAAAAAAGTTATAAAGTCTTGTTGGCAGGT 4,999 39.1
28R GAGGAGAAGCCCGGTTTATTTTATATAATCGTTGCTAAATCCCTT
23 SSA_0074 ABC transporter substrate-binding
protein-sugar transport
23F GACGACGACAAGATACCAAGTGGGGAAAATAGTAAAGGAAA 73,1344 49.2
23R GAGGAGAAGCCCGGTTTATTTCACATCAACTGCAACCGTTTC
61 SSA_0739 Carbamate kinase 61F GACGACGACAAGATAGCAAATCGTAAAATCGTTGTAGCCTT 4,945 35.4
61R GAGGAGAAGCCCGGTTTAGCCTTTTTCAATAATCGTGCCGC
31 SSA_1663 Collagen-binding protein A 31F GACGACGACAAGATCCAAGCAGCTGAGTTTGGTGATGTT 91,4452 158.7
31R GAGGAGAAGCCCGGTTTAAGAACTTTCTTCGAGTTCCCCTTA
62 SSA_0218 Sugar-binding periplasmic protein 62F GACGACGACAAGATCGAAAAAGTCCTGCGTATCGGGGTC 91,1281 51.8
62R GAGGAGAAGCCCGGTTTATTTTCCGCTTTCTATTTCTCTTTG
20 SSA_0893 ATP-binding cassette
transporter-like protein
20F GACGACGACAAGATCAGACAGATCAATCAACAACAGGCCA 94,1263 44.6
20F GAGGAGAAGCCCGGTTTAAGCTTTAACATGCTGTCCTACCT
8 SSA_1038 Lipoprotein 8F GACGACGACAAGATCAACAAAAAACAATGGCTAGGTCTTGG 4,1053 38.7
8R GAGGAGAAGCCCGGTTTATTTGTCAGGAACAGTGATGCTGC
44 SSA_0146 Possible ATPase involved in DNA
repair, contains gram positive anchor
44F GACGACGACAAGATAGCAGATGAGGAGCAGCCTGTTGC 106,2373 82.7
44R GAGGAGAAGCCCGGTTTAATCTTCCTTTTTTCTACTACGGAG
21 SSA_0753 Foldase protein prsA precursor 21F GACGACGACAAGATCAAGAAAAAAATATTTGCAGGAGCAGTG 4,1005 38.2
21R GAGGAGAAGCCCGGTTTATTCTGCGGCTGAGGATGAAGC
1 SSA_0138 Metal-binding (Zn) permease 1F GACGACGACAAGATCAAAAAAATTAGCTTACTATTAGCAGGTC 4,1500 58.1
1R GAGGAGAAGCCCGGTTTAGTGCGCCAACATCTCTTGGGC
aidentifying number.
bfragment position from 59-end to 39-end in ORF.
cmolecular weight of protein including His-tag.
doi:10.1371/journal.pone.0011666.t003
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with pET-46 Ek/LIC vector for transformation of NovaBlue
competent cells as described by the manufacturer. After the
recombinant plasmids were confirmed to have the expected inserts
by colony PCR and sequencing, they were re-transformed into E.
coli BL21(DE3)pLysS for protein expression and purification.
BL21(DE3)pLysS cells containing the appropriate plasmid were
cultured overnight in Luria-Bertani (LB) medium supplemented
with 100 mg/ml ampicillin at 30uC with shaking. The culture was
diluted 100-fold with fresh LB medium the next morning and
incubation continued until the OD600 reached approximately 0.5.
After addition of isopropyl b-D-1-thiogalactopyranoside (IPTG) to
0.1 mM to induce protein expression, the culture was incubated
with vigorous shaking at 20uC overnight (16h). Bacterial cells were
harvested by centrifugation and stored at 280uC. Lysis of the cell
pellets was performed at room temperature using BugBuster buffer
containing 25 U/mL BenzonaseH Nuclease (Novagen). After
centrifugation to remove debris at 16,0006g for 20 min at 4uC,
the supernatant was collected for protein purification. Protein was
purified using a Novagen HisNBindH Column Chromatography kit
as described in the manufacturer’s protocol. The purified protein
was dialyzed against 10 mM Tris-Cl, pH 8.0 buffer (containing
20 mM NaCl, 0.1% glycine) overnight. The protein was
concentrated using an AmiconH Ultra centrifugal filter (Millipore,
Billerica, MA).
Pooled-protein vaccination
Ten purified proteins were pooled for rabbit immunization. The
protocol received Institutional Animal Care and Use Committee
approval and complied with all applicable federal guidelines and
institutional policies. The pool containing equimolar amounts of
ten purified proteins (total 1 mg) was mixed 1:1 (v/v) with
complete Freund’s adjuvant (CFA) (Difco Laboratories, Sparks
MD) and injected subcutaneously into 3 specific-pathogen free
New Zealand White rabbits from which pre-immune serum had
been collected. For a sham vaccination control, one milligram of
His-tagged P. gingivalis Kgp protein described previously [25], also
mixed 1:1 (v/v) CFA, was used. Three weeks after initial
immunization, blood was collected and rabbits were boosted with
the identical proteins mixed 1:1 (v/v) with incomplete Freund’s
adjuvant. Three weeks later, antisera were collected for further
analysis.
Western blot
To examine the reactivity of the antisera to each protein used
for immunization, a Western blot was performed as described
[66]. Briefly, ten His-tag purified proteins (10 ng each/well) were
separated on a 7.5% SDS-PAGE gel and transferred to a
nitrocellulose membrane. The transferred membrane was blocked
with TTBS (Tris-buffered saline and 0.1% Tween 20) and 1%
BSA for 1h, and incubated at room temperature for 1 h with
1:2000 diluted antiserum. After washing with TTBS, the
membrane was incubated with 1:4000 Goat anti-rabbit IgG–AP
conjugates (Promega, Madison, WI) at room temperature for 1 h.
The color reaction of the membrane was developed with Western
Blue Stabilized Substrate for Alkaline Phosphatase (Promega).
ELISA assays
Indirect ELISA was applied to detect the titer of the antisera
against specific candidate proteins. To determine the optimal
concentrations of the reagents for ELISA, checkerboard titrations
(CBT) were performed as described [67]. Ten proteins were
optimized by criss-cross serial dilution analysis using antiserum.
Pre-immune serum was used to estimate the background. After
criss-cross serial dilution determining the optimal concentration of
antigen proteins for indirect ELISA, Immulon 2 HB microtiter
plates (Nunc, Rochester, NY) were coated with 100 ml purified
protein overnight at 4uC. After incubation with blocking buffer
and three washes with ddH2O, two-fold serial dilutions of 100 ml
antiserum (or pre-immune serum) were added and the plates were
incubated at room temperature for 2 h. After blocking and
washing again, a 4000-fold dilution of goat-anti-rabbit IgG–AP
conjugate (Promega) was added. After 2 h incubation at room
temperature, the color reactions were developed with p-nitrophe-
nyl phosphate (Sigma, St. Louis, MO) and the absorbance was
measured at 405 nm. Titers of protein-specific antibodies were
defined as the dilution that gave an OD405 value 0.1 higher than
the pre-immune serum background.
For whole-cell ELISA, 106 colony-forming units (CFU) of S.
sanguinis SK36 cells harvested at early stationary phase were coated
onto plate wells according to a method described previously [36].
The antiserum was added and allowed to interact with bacterial
surface proteins. After removing the free antiserum by five washes
with 200 ul PBST each, the bound antiserum was quantified by
adding goat-anti-rabbit IgG–AP, as with the indirect ELISA.
For competitive ELISA, affinity-purified antibodies were 2-fold
serially diluted in 96-well untreated polystyrene microtiter plates
(Nunc, Thermo Scientific, Waltham, MA). Two sets of serially
diluted samples for each purified antibody were prepared. One
diluted sample was mixed with its specific antigen at a final
concentration of 10 mg/ml in each well. The other diluted samples
were mixed with BSA only. Mixtures were incubated at 37uC for
1 h with gently shaking. After incubation, the mixtures were
transferred to the S. sanguinis SK36 cell-coated plate wells and
incubated at 37uC for 1 h. After removing the free antibodies by
five washes with 200 ul PBST, the bound antibodies were detected
by indirect ELISA, as described above.
Antiserum affinity purification
To purify antigen-specific antibody from the pool-immunized
antiserum, affinity chromatographic purification was performed
using AminoLink Plus Column kits (Pierce Protein Research
Products, Rockford, IL) according to the manufacturer’s protocol.
Briefly, the purified proteins without Tris were first covalently
linked on solid AminoLink Plus Columns with sodium cyanobor-
ohydride solution. After blocking the remaining active sites of the
column with Quenching Buffer and washing away reactants and
non-coupled protein, the antiserum was loaded on the column.
After four washes with Coupling Buffer (Pierce Chemical
Company), the affinity purified antibody was eluted using
ImmunoPure Gentle Ag/antibody buffer (Pierce Protein Research
Products). The elution fractions of interest were pooled by
checking absorbance at 280 nm. After dialysis, the purified
immunoglobulins were concentrated with AmiconH Ultra centrif-
ugal filters (Millipore). The immunoglobulin concentrations were
determined by OD280 and equivalently diluted. Serial dilutions of
the purified immunoglobulins were assayed using ELISA to
examine their purity and specificity.
FACS analysis
FACS analysis was carried out as described previously [5].
Briefly, S. sanguinis SK36 were grown in Todd-Hewitt broth (Difco
Inc.) to an OD660 of 0.6. Bacteria were collected by centrifugation,
washed twice with PBS and incubated with newborn calf serum
(Sigma) for 20 min at room temperature. The harvested cells were
then incubated at 4uC for 1 h in 200 ml of pre-immune sera,
immune sera, or affinity-purified antibody pretreated with or
without its specific antigen (to final concentration 10 mg/ml) for
1 h at 4uC. After centrifugation and washing with 0.1% BSA in
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PBS, cells were incubated at 4uC for 1 h with 50 ml of R-
phycoerythrin-conjugated F(ab)2 goat anti-rabbit IgG (Pierce
Protein Research Products) diluted 1:100 in PBS containing
0.1% BSA and 20% newborn calf serum. Bacteria were washed
with 0.1% BSA in PBS, resuspended in 200 ml PBS and analyzed
using a flow cytometer (Guava EasyCyte Mini System, Guava
Technologies, Hayward, CA). FACS data were analyzed by the
program Win MDI 2.9.
Opsonophagocytosis
Specific phagocytic activity in the presence of each affinity
purified antibody was measured in vitro as described [37]. Human
PMNs were isolated from buffy coat blood (Virginia Blood Service)
using sedimentation through a solution of hydroxyethyl starch
followed by density centrifugation over Histopaque (Sigma)
according to the manufacturer’s protocol. Phagocytosis was
examined in a reaction of 125 ml containing ,26106 human
PMNs, ,76106 CFU of S. sanguinis SK36 cells, 10% rabbit
complement (Sigma), and affinity-purified antibody with shaking
at 250 rpm at 37uC for 1 h. After 0 or 1 h of incubation, the
mixture was diluted in sterile ddH2O and plated on BHI agar
plates.
Statistical analysis
Competitive ELISA and FACS data were analyzed by unpaired
Student’s test based on their titer and geometric mean fluorescence
intensity, respectively. Other data on ELISA and opsonophago-
cytosis were examined by ANOVA with a Dunnett multiple-
comparison post hoc test. P,0.05 represents a statistically
significant difference.
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